Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 8/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 5/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.44 |
| ▸ | ESR1 | P03372 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.44 |
| ▸ | RNASEL | Q05823 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22263931 | 0.96 | TSHR (0.55) | TSHRL3MBTL1TDP1MAPK1CYP3A4 | |
| SCHEMBL22263841 | 0.94 | ALDH1A1 (0.56) | TSHRL3MBTL1TDP1MAPK1CYP3A4 | |
| SCHEMBL8942783 | 0.94 | ALDH1A1 (0.56) | TSHRL3MBTL1TDP1MAPK1CYP3A4 | |
| SCHEMBL22263901 | 0.94 | ALDH1A1 (0.56) | TSHRL3MBTL1TDP1MAPK1CYP3A4 | |
| SCHEMBL4722815 | 0.91 | ALDH1A1 (0.51) | TSHRL3MBTL1TDP1MAPK1CYP3A4 | |
| SCHEMBL4723198 | 0.88 | TSHR (0.50) | TSHRL3MBTL1TDP1MAPK1CYP3A4 | |
| SCHEMBL2323796 | 0.85 | TSHR (0.49) | TSHRL3MBTL1MAPK1ALDH1A1HSD17B10 | |
| SCHEMBL7196364 | 0.82 | ESR1 (0.51) | TSHRL3MBTL1TDP1MAPK1CYP3A4 | |
| SCHEMBL6555872 | 0.80 | PPARG (0.33) | TSHRTDP1MAPK1SMN1; SMN2KDM4E | |
| SCHEMBL6946454 | 0.80 | TSHR (0.61) | TSHRL3MBTL1TDP1MAPK1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2514402-B1 | PREVENTING OR AMELIORATING AGENT FOR PIGMENTATION | POLA CHEM IND INC (JP) | 2016-08-31 | — | — | EP | disclosed |
| US-9414998-B2 | Preventing or ameliorating agent for pigmentation | POLA CHEMICAL INDUSTRIES INC. (JP) | 2016-08-16 | — | — | US | disclosed |
| US-20140322150-A1 | PREVENTING OR AMELIORATING AGENT FOR PIGMENTATION | POLA CHEMICAL INDUSTRIES INC. (JP) | 2014-10-30 | — | — | US | disclosed |
| EP-2514402-A1 | PROPHYLACTIC OR AMELIORATING AGENT FO PIGMENTATION | Pola Chemical Industries Inc. (JP) | 2012-10-24 | — | — | EP | disclosed |
| US-20120258063-A1 | PREVENTING OR AMELIORATING AGENT FOR PIGMENTATION | POLA CHEMICAL INDUSTRIES INC. (JP) | 2012-10-11 | — | — | US | disclosed |
| US-20080176857-A1 | 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors | PFIZER INC. | 2008-07-24 | — | — | US | disclosed |
| EP-1919907-A2 | HETEROCYCLIC COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2008-05-14 | — | — | EP | disclosed |
| EP-1874780-A1 | 4-PIPERAZINYLTHIENO[2,3-D]PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS | Pharmacia & Upjohn Company LLC (US) | 2008-01-09 | — | — | EP | disclosed |
| WO-2007026959-A2 | DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZ0 [B] THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-03-08 | — | — | WO | disclosed |
| WO-2006100591-A1 | 4-PIPERAZINNYLTHIENO [2,3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176857-A1 | 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors | TBXA2R, P2RY4, PF4 | TSHR 499/4885L3MBTL1 3954/4885TDP1 1332/4885 |
| US-20140322150-A1 | PREVENTING OR AMELIORATING AGENT FOR PIGMENTATION | TYR, MC1R, MITF | TSHR 1691/4885L3MBTL1 1212/4885TDP1 4054/4885 |
| US-20120258063-A1 | PREVENTING OR AMELIORATING AGENT FOR PIGMENTATION | TYR, MC1R, MITF | TSHR 1691/4885L3MBTL1 1212/4885TDP1 4054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.